GlassScriptPhysician profile
Jessica Mclemore
NPI 1063945616
$12,921.70
in general payments reported to CMS, 2019-2025
53 companies · $3,375 in 2025
The $3,375 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $554 · 2022: $2,678 · 2023: $3,022 · 2024: $3,293 · 2025: $3,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,690.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,823.85 | 2021-2025 | |
| Ucb, INC. | $1,020.27 | 2022-2025 | Briviact, Rystiggo, Zilbrysq |
| Amgen INC. | $1,007.68 | 2021-2025 | Uplizna, Aimovig |
| Novartis Pharmaceuticals Corporation | $996.43 | 2021-2025 | |
| Pfizer INC. | $983.62 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $798.14 | 2021-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $570.93 | 2022-2025 | Nuplazid |
| Argenx US, INC. | $525.84 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $474.66 | 2024-2025 | Hizentra |
| Lundbeck LLC | $418.81 | 2023-2025 | Vyepti, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $360.04 | 2023-2025 | Hyqvia, Gammagard |
| Catalyst Pharmaceuticals, INC. | $321.22 | 2024-2025 | |
| Genentech USA, INC. | $315.76 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Janssen Pharmaceuticals, INC | $311.65 | 2021-2023 | Ponvory |
| Acorda Therapeutics, INC | $267.13 | 2021-2023 | Inbrija |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $262.35 | 2023-2024 | Zeposia |
| Biogen, INC. | $237.28 | 2022-2025 | Tysabri, Vumerity, Leqembi |
| Lilly USA, LLC | $202.61 | 2022-2025 | Emgality, Amyvid, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $166.24 | 2022 | |
| Sk Life Science, INC. | $155.22 | 2022-2025 | |
| Emd Serono, INC. | $153.73 | 2024-2025 | |
| Octapharma USA, INC. | $141.31 | 2023-2025 | Panzyga |
| Impel Pharmaceuticals INC. | $133.83 | 2023 | Trudhesa |
| Horizon Therapeutics Plc | $128.67 | 2021-2023 | Uplizna |
| Alnylam Pharmaceuticals INC. | $128.47 | 2024-2025 | Amvuttra |
| Otsuka America Pharmaceutical, INC. | $108.43 | 2023-2025 | Rexulti |
| Mallinckrodt Hospital Products INC. | $107.42 | 2022-2024 | Acthar |
| Teva Pharmaceuticals USA, INC. | $96.18 | 2022-2025 | Austedo Xr, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $89.14 | 2021 | |
| Tanabe Pharma America, INC. | $71.54 | 2023-2025 | Radicava |
| Axsome Therapeutics, INC. | $45.22 | 2025 | Symbravo |
| Amneal Pharmaceuticals LLC | $43.70 | 2023-2025 | Rytary, Crexont |
| Neurelis, INC. | $37.04 | 2024-2025 | Valtoco |
| Boston Scientific Corporation | $32.34 | 2022-2024 | Infinion 16 |
| Ani Pharmaceuticals, INC. | $30.95 | 2024 | Purified Cortrophin Gel |
| Arbor Pharmaceuticals, INC. | $30.77 | 2022 | |
| Aucta Pharmaceuticals, INC. | $24.75 | 2025 | Motpoly Xr |
| Alexion Pharmaceuticals, INC. | $24.17 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $24.15 | 2021 | |
| Cycle Pharmaceuticals INC | $22.28 | 2024 | Tascenso Odt |
| Amylyx Pharmaceuticals, INC. | $21.64 | 2023 | Relyvrio |
| Ge Healthcare | $19.88 | 2023 | |
| Jazz Pharmaceuticals INC. | $19.87 | 2023 | |
| Grifols USA, LLC | $19.22 | 2023 | Gamunex-C |
| Tonix Medicines, INC. | $19.05 | 2025 | Tonmya |
| Greenwich Biosciences, INC. | $18.52 | 2021 | |
| Genzyme Corporation | $17.55 | 2025 | |
| Sobi, INC | $17.54 | 2021 | |
| Janssen Biotech, INC. | $16.19 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.76 | 2024 | Wainua |
| Philips North America LLC | $14.79 | 2024 | (Cm9) Amb Mon & Diag Und |
| Zogenix INC. | $14.34 | 2021 | |
| Azurity Pharmaceuticals, INC. | $13.53 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Mclemore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.